U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma ...

Related Keywords

United Kingdom ,Lugano ,Ticino ,Switzerland ,Canada ,Japan ,Texas ,United States ,Houston ,Hemophagocytic Lymphohistiocytosis ,Meghan Gutierrez ,Bristol Myers Squibb ,Michael Wang ,Bryan Campbell ,John Cunningham ,Youtube ,Instagram ,European Union ,Division Of Cancer Medicine ,Lymphoma Research Foundation ,University Of Texas Md Anderson Cancer Center ,Twitter ,Linkedin ,Drug Administration ,Department Of Lymphoma ,Exchange Commission ,Facebook ,Important Safety Information ,Cytokine Release Syndrome ,Neurologic Toxicities ,Secondary Hematological ,Cell Therapy ,Bristol Myers ,Puddin Clarke Endowed Professor ,Cancer Medicine ,Cancer Center ,Clinical Oncology ,Lymphoma Research ,Myers Squibb ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Prescribing Information ,Medication Guide ,Better Future ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,